Adjuvant melanoma treatment guided by response to targeted drugs
Treatments studied
Part of Cancer, Skin clinical trials.
This early-phase study looks at whether people with melanoma can get the “right” follow-up (extra) treatment based on how well their cancer responds after starting targeted drugs before surgery. The goal is to improve outcomes while better matching treatment to each person’s tumor response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and able to give consent
- Have melanoma confirmed by pathology testing
- Have a specific melanoma gene change called BRAF V600 mutation
- Have stage III or stage IV melanoma (as defined by cancer staging rules)
- Be well enough to function day-to-day (ECOG 0–2) and meet blood/liver/kidney test thresholds
- Cannot be pregnant or breastfeeding, and must use approved birth control if able
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how doctors use encorafenib plus binimetinib for real-world care in people with BRAF V600–mutated melanoma that can’t be removed by surgery or has spread. It may help improve understanding of which patients benefit and what happens in everyday clinical practice.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
This Phase 1 trial tests a combination of targeted cancer medicines to treat melanoma that has spread or cannot be removed by surgery. It is for people whose tumor has a specific BRAF mutation, and who have either stayed stable on a prior targeted treatment or no longer respond to it.
This Phase 2 trial tests two targeted medicines (binimetinib and encorafenib) for melanoma that has spread to the brain. It focuses on people whose tumor has a specific BRAF V600 mutation and who have brain metastases that are progressing or need treatment.
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
Hear when a new Melanoma Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.